Explore the words cloud of the TREGeneration project. It provides you a very rough idea of what is the project "TREGeneration" about.
The following table provides information about the project.
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
|Coordinator Country||Portugal [PT]|
|Total cost||5˙899˙250 €|
|EC max contribution||5˙899˙250 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-01-01 to 2019-12-31|
Take a look of project's partnership.
|1||INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES||PT (LISBOA)||coordinator||1˙792˙894.00|
|2||KLINIKUM DER UNIVERSITAET REGENSBURG||DE (REGENSBURG)||participant||1˙348˙823.00|
|3||MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV||DE (MUENCHEN)||participant||741˙335.00|
|4||AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO S. ORSOLA MALPIGHI||IT (BOLOGNA)||participant||617˙080.00|
|5||UNIVERSITE DE LIEGE||BE (LIEGE)||participant||496˙200.00|
|6||SERVICIO ANDALUZ DE SALUD||ES (SEVILLA)||participant||290˙420.00|
|7||ALACRIS THERANOSTICS GMBH||DE (BERLIN)||participant||277˙500.00|
|8||THE UNIVERSITY OF LIVERPOOL||UK (LIVERPOOL)||participant||246˙077.00|
|9||GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG||DE (MUENCHEN)||participant||88˙919.00|
Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy. The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells. Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.
|Twitter, Facebook, LinkedIn, Account Setup||Websites, patent fillings, videos etc.||2019-05-08 12:01:41|
|Launch of website||Websites, patent fillings, videos etc.||2019-05-08 12:01:37|
|Individualized press release for every partner||Websites, patent fillings, videos etc.||2019-05-08 12:01:32|
|Development of the project logo||Websites, patent fillings, videos etc.||2019-05-08 12:01:20|
Take a look to the deliverables list in detail: detailed list of TREGeneration deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREGENERATION" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TREGENERATION" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Global Alliance for Chronic Diseases SecretariatRead More